Actively Recruiting
Phase 12a Study Evaluating HMPL-A251 Safety, Tolerability, and Preliminary Efficacy in Adults with Advanced or Metastatic HER2-Expressing Solid Tumors
Led by Hutchmed · Updated on 2026-09-22
147
Participants Needed
15
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying HMPL-A251, a drug being tested for safety, tolerability, and effectiveness in adults with unresectable, advanced, or metastatic HER2-expressing solid tumors. This first-in-human, open-label, multicenter study aims to find the best dose to use in future phases and to observe how participants respond to the treatment. The study is sponsored by Hutchmed and involves phases 1 and 2a to evaluate the drugs effects in solid tumors previously treated. Participants will receive HMPL-A251 through an intravenous infusion. The study has two parts a dose escalation phase where different dose levels are tested to find the maximum tolerated dose or recommended dose for further study, and a dose expansion phase where participants are randomized to receive one of two recommended dose levels. Treatment continues until the disease progresses, unacceptable side effects occur, or other protocol criteria are met. Throughout the study, participants will undergo evaluations including safety assessments, monitoring of side effects, and scans to measure tumor response based on RECIST criteria. Researchers will collect data on treatment-emergent adverse events, response rates, disease control, survival, and drug levels in the blood over approximately two years. Participants will be closely monitored with regular visits and assessments to track their progress and study outcomes during and after treatment.
CONDITIONS
Brief Title
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here